<DOC>
	<DOC>NCT02328625</DOC>
	<brief_summary>This registry study will assess the safety and performance of the Celution Device in the processing of an autologous graft consisting of adipose derived regenerative cells (ADRCs) in the treatment of hand scleroderma.</brief_summary>
	<brief_title>Scleroderma Treatment With Celution Processed ADRCs Registry</brief_title>
	<detailed_description>This registry study will assess the safety and performance of the Celution System in preparation of adipose derived regenerative cells in the treatment of scleroderma affecting the hands. This will be a multi-center, multi-national study.</detailed_description>
	<mesh_term>Scleroderma, Systemic</mesh_term>
	<mesh_term>Scleroderma, Diffuse</mesh_term>
	<mesh_term>Scleroderma, Localized</mesh_term>
	<criteria>Diagnosis of scleroderma and presence of hand scleroderma Cochin score ≥ 20 units Body Mass Index &lt; 17 kg/m2 Infection in any finger Stable medications for the treatment of scleroderma for ≥ 1 month Pregnant or lactating status.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Scleroderma</keyword>
	<keyword>Device</keyword>
	<keyword>ADRCs</keyword>
	<keyword>adipose derived regenerative cells</keyword>
	<keyword>hand</keyword>
</DOC>